Harpoon Therapeutics (NASDAQ: HARP) Releases Updated Phase 1 Interim Results for HPN217 in Treating Relapsed Multiple Myeloma
Harpoon Therapeutics, Inc. (NASDAQ: HARP) is engaged as a clinical-stage immune-oncology company, which is focused on the research and development ...